Subcostal Temporary Extracardiac Pacing Study

Overview

Up to 15 subjects will be enrolled to evaluate initial safety and performance of the AtaCor Temporary Pacing System. Safety will be evaluated through analysis of all Adverse Events. Performance will be evaluated through (1) the incidence of successful StealthTrac Lead placement using the MACH I Delivery Tool, (2) electrical performance measurements, such as pacing capture thresholds, sensed R-wave amplitudes, pacing impedance and skeletal muscle stimulation at rest. Appropriate sensing and pacing capture will be ascertained from ECG Holter Monitor recordings during periods of in-hospital ambulation.

Full Title of Study: “Subcostal Temporary Extracardiac Pacing Study: Clinical Study of the AtaCor Extracardiac Pacing System”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Basic Science
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 9, 2019

Detailed Description

Enrolled Subjects will have both a market-released transvenous pacing lead and investigational StealthTrac Temporary Pacing Lead placed and evaluated. During the placement procedure, diagnostic echocardiograms will be performed to detect any new pericardial effusions. Once inserted, the StealthTrac Lead will be used to deliver high rate pacing (160 to 220 BPM) in clinically appropriate Subjects, to demonstrate suitability for use in transcatheter procedures that require brief periods of temporary pacing. Lead positions will be documented using fluoroscopic images before the Subject leaves the procedure room. On the following two days after the procedure, electrical performance will be evaluated in multiple postures and appropriate pacing and sensing will be confirmed during activity using ECG Holter monitor recordings. Subjects will also be asked patient-centric questions about their experience with the StealthTrac Lead throughout the study period. Evaluations will continue for a minimum of two (2) and a maximum of seven (7) days after the index procedure. Prior to StealthTrac Lead removal, an X-Ray will be taken to document the final lead position and diagnostic echocardiography will be performed to (1) detect any latent pericardial effusions and (2) assess differences in cardiac function with intrinsic conduction and while pacing. A final follow-up will be performed 25-30 days after removal to identify any latent adverse events before the Subject exits the study.

Interventions

  • Device: Subcostal Temporary Extracardiac Pacing Lead
    • The StealthTrac Lead is designed to facilitate extracardiac temporary ventricular pacing and sensing. The distal end of the StealthTrac Lead is designed to reside within the connective tissue of the anterior mediastinum outside the pericardium. The StealthTrac Lead is delivered using the MACH I Delivery Tool, which is designed to facilitate insertion of the StealthTrac Lead through a small skin incision parallel to the sternum, without the need for fluoroscopic guidance.

Arms, Groups and Cohorts

  • Experimental: Subcostal temporary extracardiac pacing lead
    • All subjects will receive a subcostal temporary extracardiac pacing lead for a minimum of 48 hours in-hospital and undergo all protocol testing.

Clinical Trial Outcome Measures

Primary Measures

  • Safety Outcome: Number of Subjects Experiencing an Adverse Event(s)
    • Time Frame: 30 days
    • Safety will be evaluated through analysis of all Adverse Events
  • Performance Outcome: Mean Pacing Capture Threshold (V)
    • Time Frame: Up to 7 days post insertion
    • Minimum current required to pacing the heart (in multiple postures)
  • Performance Outcome: Mean Pacing Impedance (ohms)
    • Time Frame: Up to 7 days post insertion
    • Impedance measured while pacing the heart (in multiple postures)
  • Performance Outcome: Mean R-Wave Amplitude (mV)
    • Time Frame: Up to 7 days post insertion
    • R-Wave amplitudes measured while sensing the heart (in multiple postures)
  • Performance Outcome: % of R-R intervals with appropriate pacing and sensing during activity
    • Time Frame: Up to 7 days post insertion
    • ECG Holter Recordings obtained during periods of in-hospital activity

Participating in This Clinical Trial

Inclusion Criteria

1. Indicated for closed-chest cardiac invasive procedure with the potential for intra-procedural or post-procedural bradycardia and willing to be hospitalized for a minimum of 2 days post procedure. Examples of such procedures include: transfemoral transcatheter aortic valve replacement (TAVR), balloon valvuloplasty, permanent pacemaker implantation and pacing lead extractions/revisions. 2. Physically and mentally capable of providing informed consent. 3. At least 18 years of age or of legal age to provide consent as required by local and national requirements. Exclusion Criteria:

1. Contraindicated or clinically unsuitable for transvenous lead placement; 2. Implanted with an implantable cardioverter defibrillator (ICD) or transvenous defibrillation lead at the time of enrollment; 3. History of a prior sternotomy (median or partial); 4. History of prior surgery with disruption of the lung, pericardium or connective tissue between the sternum and pericardium; 5. History of significant anatomic derangement of the thorax (e.g., pectus excavatum), prior chest radiation therapy or other reasons which may cause pericardial adhesions or complicate the AtaCor Temporary Pacing System insertion procedure; 6. History of pericardial disease, pericarditis or mediastinitis; 7. History of chronic obstructive pulmonary disease (COPD); 8. NYHA functional classification IV at the time of enrollment; 9. History of congenital heart disease; 10. Patients with circumstances that prevent data collection or follow-up, including conditions that prevent ambulation and testing in multiple postures; 11. BMI ≥ 35 kg/m2; 12. History of allergies to any study device components; 13. Pregnant or lactating (current or anticipated during study follow up); and 14. Participation in any concurrent study without prior, written approval from the Sponsor.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • AtaCor Medical, Inc.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Martin Burke, D.O., Principal Investigator, AtaCor Medical
    • Adrian Ebner, M.D., Principal Investigator, Sanatorio Italiano
  • Overall Contact(s)
    • Michael P Husby, MS, MPH, 949.392.8988, michael@atacor.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.